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Peroxisome proliferator-activated receptor gamma polymorphisms have been widely associated with type 2 diabetes, although
their role in the pathogenesis of vascular complications is not yet demonstrated. In this study, a cohort of 211 type 2 diabetes,
205 obese, and 254 control individuals was genotyped for Pro12Ala, C1431T, C-2821T polymorphisms, and for a newly identiﬁed
polymorphism (A-2819G). The above-mentioned polymorphisms were analyzed by gene-speciﬁc PCR and direct sequencing of
all samples. A signiﬁcant diﬀerence was found for -2819G frequency when patients with type 2 diabetes—particularly diabetic
women with the proliferative retinopathy—were compared with healthy control individuals. In conclusion, we identiﬁed a novel
polymorphism, A-2819G, in PPARG gene, and we found it to be associated with type 2 diabetes and proliferative retinopathy in
diabetic females. In the analyzed population, this variant represents a genetic risk factor for developing the diabetic retinopathy,
whereas Pro12Ala and C1431T do not.
Copyright © 2009 Valerio Costa et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Peroxisome proliferator-activated receptor gamma (PPARG)
gene is a member of nuclear hormone receptor superfamily,
and it regulates the transcription of several genes involved
in glucose metabolism, adipocyte diﬀerentiation, lipid oxi-
dation, angiogenesis, and inﬂammation [1]. PPARγ displays
diﬀerent protein isoforms generated by diﬀerent promoters
and alternative splicing [2, 3] .T h ef u n c t i o n a lr o l eo fP P A R γ
is well documented, and its alterations have been widely
associated with metabolic diseases, such as type 2 diabetes
and obesity [4, 5].
Indeed, the most analyzed PPARG polymorphism,
Pro12Ala in the exon B [6], exerts an unclear eﬀect on rec-
eptor structure, and it seems to reduce the receptor bind-
ing aﬃnity with the responsive elements, also inducing a
decrease in transcriptional activity both with and without
PPARγ agonists [7, 8]. The common Pro12Ala polymor-
phism has been associated with increased risk of developing
type 2 diabetes, even though a recent hypothesis suggests
Pro12Ala could be involved in the aetiology of metabolic
disorders not by itself, but because of linkage disequilibrium
with other single nucleotide polymorphisms (SNPs) in the
PPARG promoter [9, 10].
Moreover, PPARG gene polymorphisms have also been
associated with micro- and macrovascular complications of
diabetes, although the few available studies do not unam-
biguously conﬁrm the role of PPARG in the pathogenesis of2 Journal of Biomedicine and Biotechnology
these complications, especially diabetic retinopathy [11–13].
Indeed,recentstudieshavedemonstratedthatPPARγ ligands
could both inhibit intraocular angiogenesis and upregulate
VEGF gene expression in several cell types [14].
To date, most of the mutation analyses focused on the
coding region of the PPARG gene [9], and only few studies
have analyzed SNPs in the regulatory region of PPARG possi-
blyassociatedwithmetabolicdisordersusceptibility[15,16].
AnovelfunctionalvariantinthePPARγ2 promoter,C-2821T,
that associates with predictors of type 2 diabetes and obesity,
was recently reported in Pima Indians population [16].
In attempt to analyze this variant in Italian individuals
aﬀected by type 2 diabetes, we have performed an SNP
analysis on 211 unrelated type 2 diabetic patients from
Campania County, Southern Italy. Subsequently, we have
extended this analysis to a cohort of 205 unrelated obese
patients and 254 control individuals.
Furthermore, we have genotyped the above-mentioned
cohort (diabetic, obese, and control individuals), for two
extensively studied SNPs in high linkage disequilibrium,
Pro12Ala and C1431T.
2.MaterialsandMethods
2.1. Patients and Clinical Characteristics. Genomic DNA was
extracted from blood samples by standard procedures [17].
SNP analysis was performed on genomic DNA from 211
unrelated Italian type 2 diabetic patients (102 of which
suﬀered from proliferative retinopathy), 205 unrelated obese
patients, and 254 control individuals. All the subjects were
recruited from the Department of Geriatrics and Metabolic
Diseases, Second University of Naples, Italy, and from the
Department of Neuroscience, “Federico II” University of
Naples, Italy. All procedures were approved by the Ethics
Boardoftheparticipatinginstitutesandadheredtothetenets
of the Declaration of Helsinki. All samples were acquired
after informed consent was obtained from the patients.
Thediabetesandobesestatusweredeterminedaccording
to the criteria of World Health Organization [18]. Patients
with type 2 diabetes were eligible for the study if they
had background or proliferative diabetic retinopathy, similar
age (±1 year) and similar duration of diabetes (±1y e a r ) .
No other inclusion criteria had to be met. The clinical
characteristics (age, sex, duration of T2DM, 2h-plasma
glucose, HbA1c and BMI) of the 102 diabetic patients with
proliferative retinopathy were not diﬀerent from those of
the 109 diabetic patients with background retinopathy (see
Table 1). Retinopathy condition was evaluated by ocular
fundus photography.
2.2. SNP Analysis and Genotyping. Pro12Ala SNP analysis
was performed with speciﬁc primers pairs (Pro12AlaF 5 -
TTT TAA CGG ATT GAT CTT TTG C-3  and Pro12AlaR
5 -ACC CTT ACA TAA ATG CCC CC-3 ) amplifying a
fragment of 214bp. C1431T SNP in the exon 6 of PPARG
genewasanalyzedbyPCRampliﬁcationofa358bpfragment
using speciﬁc primers pairs (C1431TF 5 -CTG AAC CCC
CTG TTG TGT TT-3  and C1431TR 5 -GGT GTC AGA
TTT TCC CTC AGA-3 ). The screening of C-2821T and A-
2819G SNPs was carried out on a 453bp genomic region
Table 1: Clinical characteristics of type 2 diabetic patients.
Characteristic
Proliferative Background P value
DR group DR group
n 102 109
Age (years) 63 ± 10 62 ± 90 . 4 4
Male (%) 45 (44,1) 54 (49,5) 0.51
Female (%) 57 (55,9) 55 (50,5) 0.72
Duration of T2DM 11,5 ± 2,9 12,0 ± 2.5 0.18
2h-plasma glucose (mg/dl) 230 ± 90 172 ± 60 0.001
HbA1c 8,9 ± 1, 0 7,9 ± 0,9 0.001
BMI (Kg/m2) 31,2 ± 4,4 30,4 ± 4,5 0.19
of PPARγ2-speciﬁc promoter, PCR ampliﬁed with speciﬁc
oligonucleotides (C-2821TF 5 -TAC ACC AAT GGG TTG
TCA-3 ; C-2821TR 5 -GTA GCC AAA GAC AGG TTC TG-
3 ) by Muller et al. (2003) [16].
PCR reactions set-up with AmpliTaq Gold (Applied
Biosystems, Calif, USA) were performed using an ABI 9700
automatic thermal cycler under the following conditions:
95◦C for 10 minutes; then 35 cycles of 95◦Cf o r1m i n u t e ,
at annealing temperature (Ta) for 1 minute, of 72◦Cf o r
2 minutes; and a ﬁnal step of 72◦C for 10 minutes. PCR
products were analyzed by denaturing high performance
liquid chromatography (DHPLC), and those with a DHPLC
patterndiﬀerentfromcontrolsweresequencedusingtheABI
Prism Big Dye Terminator Cycle Sequencing V2.0 (Applied
Biosystems).
2.3. Statistical Analysis. Statistical analysis was performed
using standard chi-square, Fisher, and student’s t-tests.
For continuous variables, the general estimating equation
procedure was used to adjust for covariates. The associa-
tion of polymorphisms with type 2 diabetes, obesity, and
retinopathywasanalyzedbyexactchi-squaretest,comparing
SNPs frequencies.
Allele and genotype frequencies (Pearson χ2 statistics),
O.R., and P values, as well as dominant and recessive genetic
models, were analyzed using FINETTI (http://ihg2.helm-
holtz-muenchen.de/cgi-bin/hw/hwa1.pl). Hardy-Weinberg
equilibrium of tested groups and Armitage’s trend test
(ATT) were also calculated using FINETTI. ATT takes into
account genotypes rather than alleles, avoiding a possible
bias due to doubling of sample size [19]. It assumes additive
(or codominant) disease model where all disease allele are
independent and have the same contribution to the disease
risk.
Continuous clinical data, such as duration of type 2
diabetes (years), HbA1c and BMI (body mass index-Kg/m2),
diﬀerent between background and proliferative retinopathy
populations, were compared by unpaired student’s t-test
(two-tailed test); a resulting P v a l u el e s st h a n0 . 0 5( C . I .9 5 % )
was considered signiﬁcant.
3. Results
To investigate whether SNPs in the PPARG gene could be
a risk factor for type 2 diabetes and obesity, an extensiveJournal of Biomedicine and Biotechnology 3
Table 2: Genotypes and allele frequencies in diabetic, obese, and control groups (statistical signiﬁcant values are in bold).
(a)
Control group Diabetic group Obese group
n 254 211 205
Pro12Ala
Pro/Pro 222 (87,5%) 179 (84,6%) 176 (86%)
Pro/Ala 32 (12,5%) 32 (15,4%) 28 (13,6%)
Ala/Ala 0 (0%) 0 (0%) 1 (0,4%)
C1431T
C/C 199 (78,3%) 171 (81%) 176 (85,9%)
C/T 44 (17,4%) 38 (18%) 27 (13,2%)
T/T 11 (4,3%) 2 (1%) 2 (0,9%)
A-2819G
A/A 208 (81,7%) 141 (66,7%) 165 (80,6%)
A/G 39 (15,4%) 64 (30,6%) 36 (17,6%)
G/G 7 (2,9%) 6 (2,7%) 4 (1,8%)
(b)






group Control/Diabetic Control/Obese Control/Diabetic Control/Obese
0.06 0.08 0.08 1.2 (0.73–2.03) 1.1 (0.70–1.96) 0.4; 23% 0.5; 12.2%
C1431T T
0.13 0.10 0.07 0.74 (0.49–1.1) 1.83 (1.17–2.86) 0.1; 17.6% 0.008; 68.3%
A-2819G G
0.10 0.18 0.10 2.25 (1.46–3.44) 1.03 (0.67–1.57) 1.9 ×10
−4; 98% 0.9; 9%
Table 3: Hardy-Weinberg equilibrium and association tests for A-2819G SNP.
Hardy-Weinberg equilibrium Tests for association (C.I.: 95% conﬁdence interval)
Controls Diabetic group Risk allele Armitage’s trend test
n = 254 n = 211 [AA versus GG] [AA versus AG+GG] Common odd ratio
O.R. = 2.42 O.R. = 2.24 O.R. = 1.60
C.I. = [0.41–3.84] C.I. = [1.46–3.44]
P = .01 P = .8 P = .6 P = 1.9 ×10
−4 P = .0013
polymorphism analysis in a population of 670 individuals
from Campania County, in Southern Italy, was performed.
The diabetes and obese status were determined according to
the criteria of World Health Organization.
We genotyped three SNPs, Pro12Ala, C1431T—in the
coding region of PPARG gene—and C-2821T in the regu-
latory region [16], in 211 individuals with type 2 diabetes,
205 suﬀering from obesity, and 254 control individuals. Our
analysis revealed that T-2821 allele was not found in 670
individuals, and consequently, C-2821 allele frequency was
100%.
Allelic frequencies of Pro12Ala and C1431T variants
(listed in Table 2) are in agreement to the data previously
reported by Doney et al., 2004 [20], although 1431T allele
was shown to be less frequent in obese than in control
individuals in the analyzed population.
Moreover, during the SNP analysis of the C-2821T SNP,
we have characterized a novel SNP, A-2819G, located two
base pair downstream, included within the same putative E2
box[16]. This novel SNP was genotyped on the entire cohort
of 670 individuals using the same standard procedures.
Genotypes and allelic frequencies of A-2819G are reported
in Table 2.
The -2819G minor allele frequency, observed in 211
individuals with type 2 diabetes, was about 2-fold than the
frequency of the risk allele in the control and obese groups
(see Table 2). In logistic regression analyses, aimed to test the
hypothesisofA-2819Gasriskfactorfortype2diabetesunder
the assumption of a codominant, recessive and dominant
model, the dominant model best ﬁtted the data (P =
1.9 × 10
−4, Table 3). According to this model, -2819G allele
c a r r i e r s( A Ga n dG Gg e n o t y p e )s h o w e da nO . R . = 2.244 Journal of Biomedicine and Biotechnology
Table 4: Genotypes and -2819G frequency in diabetic women with and without proliferative retinopathy (statistical signiﬁcant values are in
bold).
(a)
Diabetic female with background retinopathy Diabetic female with proliferative retinopathy
n 55 57
A-2819G
A/A 43 (78%) 34 (60%)
A/G 11 (22%) 21 (36.7%)
G/G 0 (0%) 2 (3.3%)
(b)
SNP Risk allele Frequency of risk
















































Statistical signiﬁcant values ∗∗
Figure 1: Comparison of A-2819G frequencies in diabetic women
with background or proliferative retinopathy and control women.
(95%C.I.1.46–3.44)ofdevelopingtype2diabetescompared
to the noncarriers (Table 3). The A-2819G allele is in Hardy-
Weinberg disequilibrium (DHW) in the control group (P =
.01 see Table 3).
The newly identiﬁed risk allele -2819G was not found
to be associated with obesity (Table 2) and it was estimated
to be not in linkage disequilibrium with Pro12Ala and
C1431T SNPs. The possible association of A-2819G SNP
with some speciﬁc clinical features of both type 2 diabetes
and obesity was also considered. Speciﬁcally, BMI in obese
individuals, blood glucose, and HA1c levels and the presence
of proliferative retinopathy in type 2 diabetic patients were
evaluated. The analysis revealed that -2819G frequency in
diabetic females with proliferative retinopathy was 2-fold
increased with respect to background retinopathy female
(P = .02; see Table 4 and Figure 1).
In logistic regression analyses, the dominant model best
ﬁtted the data (P = .03; see Table 5). According to this
model,type2diabetesfemalewith-2819Gallele(AGandGG
genotype) showed an O.R. = 2.42 (95% C.I. = 1.057–5.56)
of developing proliferative retinopathy compared to the
noncarrier diabetic female (Table 5). The A-2819G allele is
in Hardy-Weinberg equilibrium in both background and
proliferative groups (Table 5). Moreover, diabetic females
with proliferative retinopathy had more than 3-fold risk
compared to control females (data not shown).
In conclusion, our results show that a novel nucleotide
variant A-2819G, in the regulatory region of PPARG, is asso-
ciated with type 2 diabetes and with proliferative retinopathy
in females in an Italian cohort.
4. Discussion
Previous studies have shown that nucleotide variations, both
point mutations and SNPs, in the PPARG coding region,
are associated with an increased susceptibility of developing
type 2 diabetes and obesity [9]. Particularly, the well-known
Pro12Ala substitution has been widely associated with both
type 2 diabetes and obesity, or predictors of these diseases, in
diﬀerent populations [10, 12]. The Pro12Ala polymorphism
has been recently predicted to confer protection, through
unknown mechanisms, from type 2 diabetes and nephropa-
thy [12, 15, 21, 22].
Conversely,ithasalsobeenshownthatPro12Aladoesnot
associate with diabetic retinopathy [11, 13]. The Pro12Ala
SNP has been described in high linkage disequilibrium with
C1431T polymorphism, located in exon 6 of PPARG gene.
Several studies have shown T minor allele to be associated, in
obese individuals, with low plasmatic leptin levels [14]. The
same variation has been associated with high BMI values in
obese female from Finland in coassociation with Ala12 allele
[23].
In the present study, we demonstrated that Pro12Ala and
C1431T variants are not associated with type 2 diabetes,Journal of Biomedicine and Biotechnology 5
Table 5: Hardy-Weinberg equilibrium and association tests for A-2819G and proliferative retinopathy.
Hardy-Weinberg equilibrium Tests for association (C.I.: 95% conﬁdence interval)
Background Proliferative Risk allele Armitage’s trend test
n = 55 n = 57 [AA versus GG] [AA versus AG+GG] Common odd ratio
O.R. = 6.30 O.R. = 2.42 O.R. = 3.57
C.I. = [0.29–135.68] C.I. = [1.057–5.56]
P = .37 P = .57 P = .12 P = .03 P = .02
obesity, BMI variation, and also microangiopatic compli-
cation of diabetes, in a cohort of 670 individuals from
Campania County, in the Southern Italy. We also found that
-2821Tallele,describedinthePimaIndianspopulationfrom
Arizona, was not present in the analyzed population.
In contrast, a novel nucleotide variation, A-2819G, two
base pair downstream the C-2821T SNP described by Muller
et al. [16], was identiﬁed. We demonstrated that the A-
2819G nucleotide variant is associated with type 2 diabetes,
but not with obesity or BMI variations (Tables 2 and 3).
The A-2819G allele is in DHW in the control group. DHW
may be due to several factors such as genotyping errors,
population stratiﬁcation, selection, inbreeding, the presence
ofacausativealleleorsimplybythechance.Wecantherefore
excludewithhighconﬁdencethatDHWinthecontrolgroup
could be due to genotyping errors. For A-2819G SNP, as well
as for all the examined SNPs, all the subjects were analyzed
by DHPLC and then sequenced. We cannot exclude that
DHW is due to other confounding factors; however, at least
for the autosome genes, the presence of DHW in controls
is compatible with the segregation of a causative variant
according to a dominant model [24].
The association tests for the newly identiﬁed A-2819G
SNP, revealed statistical signiﬁcant association with a com-
mon and detrimental microvascular complication of type 2
diabetes,namely,thediabeticproliferativeretinopathy,inthe
diabetic females of the examined population (O.R. = 2.43;
C.I. 1.09–4.83; P = 0.02). This microvascular complication
represents a leading cause of blindness, characterized by an
increased vascular permeability, haemostatic abnormalities,
increased tissue ischemia, and also neoangiogenesis.
ThenewlyidentiﬁedA-2819GSNPandtheC-2821T[16]
are both located in a binding site for a transcriptional repres-
sor δEF1. The polymorphisms described by Muller et al.,
2003 [16], leading to higher levels of PPARG transcription,
has been associated with an increased risk of development of
type2diabetesandobesityinPimaIndians[16].Thisﬁnding
is supported by the notion that supraphysiological activation
of PPARγ by thiazolidinedione (TZD) agonists increases
triglyceride (TG) content of white adipose tissue, thereby
decreasing TG levels in the liver and muscles, resulting in
increased insulin sensitivity and type 2 diabetes [25].
In this study, we demonstrated that a novel polymor-
phism, in the regulatory region of PPARG, associates to
proliferative retinopathy in diabetic females, suggesting a
possible involvement of the hormonal female component,
such as the estrogen receptor signaling that interferes with
the physiological PPARγ intracellular pathway [26]. We can
reject sex diﬀerences due to genotype bias, since males and
females were analyzed together, in blind fashion, and the
gender was assigned after the analysis.
We postulate that PPARγ may be involved in the
development and progression of diabetic retinopathy via a
plethora of mechanisms, although its pathogenic eﬀect on
the development of the microvascular complications in type
2 diabetic patients is not yet known.
Indeed, Muller et al. (2003) concluded that -2821T allele,
via its eﬀect on PPARγ expression, may exert functional
consequences on diﬀerent PPARγ2-activated pathways and
that its association with the well-known Pro12Ala may
contribute to PPARγ2-related phenotypes [16].
PPARγ is a multivalent receptor able to bind diﬀerent
ligands. Full and partial TZD agonists can induce distinct
receptor combinations, leading to selective gene expres-
sion. Ligand-receptor complexes, assuming diﬀerent three-
dimensional conformations, show unique and diﬀerential
interactions with cofactors and other transcription factors
[27].
Particularly, PPARγ2 is highly and heterogeneously
expressed in the human eye, where its ligand-dependent
activation evokes potent and robust inhibition of corneal
angiogenesis [27]. Moreover, altered lipid oxidation in the
retina supporting cells (retinal pigment epithelium, RPE)
and in the eye vessels, and an increased glucose uptake from
RPE cells, has pathological eﬀects on eye vessels [28, 29].
However, it was already shown that lipid peroxidation is
inﬂuenced by C1431T polymorphism, also involved in the
susceptibility to premature myocardial infarction [30].
We hypothesize that the newly identiﬁed A-2819G
nucleotide variation—possibly altering PPARγ2 transcript
abundance—may aﬀect the complex and highly regulated
gene expression network in the eye, conferring in turn the
susceptibility to diabetic retinopathy.
Further studies enrolling a greater number of subjects,
both patients and controls, would be useful to better eluci-
date the involvement of this novel SNP in the susceptibility
of developing diabetic retinopathy. However, these ﬁndings
strengthen the hypothesis that PPARγ could be a novel
pharmacological target of angiostatic agents in the treatment
of diabetic retinopathy.
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